Prosight Management LP Sells 422,668 Shares of Kura Oncology, Inc. $KURA

Prosight Management LP lessened its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 13.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,758,516 shares of the company’s stock after selling 422,668 shares during the period. Kura Oncology makes up about 5.7% of Prosight Management LP’s portfolio, making the stock its 4th biggest holding. Prosight Management LP owned about 3.17% of Kura Oncology worth $24,413,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after buying an additional 2,977 shares in the last quarter. Strs Ohio purchased a new stake in Kura Oncology in the first quarter valued at about $143,000. Savant Capital LLC boosted its holdings in Kura Oncology by 74.1% in the second quarter. Savant Capital LLC now owns 87,974 shares of the company’s stock worth $508,000 after acquiring an additional 37,450 shares in the last quarter. Fox Run Management L.L.C. boosted its holdings in Kura Oncology by 31.5% in the second quarter. Fox Run Management L.L.C. now owns 31,546 shares of the company’s stock worth $182,000 after acquiring an additional 7,557 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Kura Oncology during the second quarter worth about $450,000.

Analyst Ratings Changes

KURA has been the topic of several recent analyst reports. Leerink Partners set a $20.00 price objective on shares of Kura Oncology and gave the company an “outperform” rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. UBS Group restated a “buy” rating and set a $15.00 price target (down from $16.00) on shares of Kura Oncology in a research note on Friday. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $27.57.

Kura Oncology Trading Down 2.1%

Shares of NASDAQ:KURA opened at $8.65 on Friday. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $12.49. The stock has a market cap of $764.05 million, a price-to-earnings ratio of -2.72 and a beta of 0.22. The company has a quick ratio of 6.05, a current ratio of 6.06 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $8.62 and a 200-day moving average price of $9.45.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 102.59%. The firm had revenue of $17.34 million during the quarter, compared to analysts’ expectations of $34.71 million. Equities analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 11,208 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $94,819.68. Following the completion of the sale, the insider directly owned 226,931 shares in the company, valued at approximately $1,919,836.26. The trade was a 4.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Brian T. Powl sold 6,414 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $54,262.44. Following the completion of the sale, the insider directly owned 183,275 shares in the company, valued at $1,550,506.50. This trade represents a 3.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 59,794 shares of company stock worth $537,176. Corporate insiders own 6.40% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.